Arcutis Biotherapeutics (ARQT) EBIAT: 2021-2025
Historic EBIAT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.4 million.
- Arcutis Biotherapeutics' EBIAT rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
- Arcutis Biotherapeutics' EBIAT amounted to $7.4 million in Q3 2025, which was up 146.64% from -$15.9 million recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' EBIAT ranged from a high of $7.4 million in Q3 2025 and a low of -$107.7 million during Q3 2022.
- For the 3-year period, Arcutis Biotherapeutics' EBIAT averaged around -$39.6 million, with its median value being -$41.5 million (2024).
- In the last 5 years, Arcutis Biotherapeutics' EBIAT tumbled by 89.03% in 2022 and then soared by 117.84% in 2025.
- Over the past 5 years, Arcutis Biotherapeutics' EBIAT (Quarterly) stood at -$71.3 million in 2021, then dropped by 0.97% to -$72.0 million in 2022, then grew by 7.96% to -$66.3 million in 2023, then surged by 83.72% to -$10.8 million in 2024, then soared by 117.84% to $7.4 million in 2025.
- Its EBIAT was $7.4 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$25.1 million in Q1 2025.